Renuvion® receives fda clearance for specific use after liposuction

Apyx medical's renuvion becomes the only device that is fda-cleared for use following liposuction in aesthetic body contouring procedures clearwater, fla. , may 2, 2023 /prnewswire/ -- apyx medical corporation (nasdaq: apyx), the manufacturer of the proprietary helium plasma and radiofrequency technology marketed and sold as renuvion®, today announced that it has received 510(k) clearance from the u.s. food and drug administration ("fda") for the use of its apr handpiece in procedures for coagulation of soft tissues following liposuction, the most popular plastic surgery procedure in the world.
APYX Ratings Summary
APYX Quant Ranking